In several studies, high levels of circulating sPD-L1 were associated with poor patient outcomes in melanoma, lung and gastric cancers and lymphoma [155,158,159,160] and with reduced response to PD-1 blockade in melanoma [161]. This evidence concerns the gene SPDL1 and melanoma.